These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9182838)
21. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413 [TBL] [Abstract][Full Text] [Related]
22. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression. Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404 [TBL] [Abstract][Full Text] [Related]
23. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785 [TBL] [Abstract][Full Text] [Related]
24. Concomitant treatment with mild hyperthermia, cisplatin and low dose-rate irradiation in human ovarian cancer cells sensitive and resistant to cisplatin. Raaphorst GP; Maio J; Ng CE; Stewart DJ Oncol Rep; 1998; 5(4):971-7. PubMed ID: 9625857 [TBL] [Abstract][Full Text] [Related]
25. Cytotoxic enhancement of low dose-rate irradiation in human lung cancer cells by mild hyperthermia. Sakurai H; Mitsuhashi N; Kitamoto Y; Nonaka T; Harashima K; Higuchi K; Muramatsu H; Ebara T; Ishikawa H; Niibe H Anticancer Res; 1998; 18(4A):2525-8. PubMed ID: 9703904 [TBL] [Abstract][Full Text] [Related]
26. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
27. Interaction between low dose-rate irradiation, mild hyperthermia and low-dose caffeine in a human lung cancer cell line. Sakurai H; Mitsuhashi N; Tamaki Y; Akimoto T; Murata O; Kitamoto Y; Maebayashi K; Ishikawa H; Hayakawa K; Niibe H Int J Radiat Biol; 1999 Jun; 75(6):739-45. PubMed ID: 10405004 [TBL] [Abstract][Full Text] [Related]
28. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765 [TBL] [Abstract][Full Text] [Related]
29. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Masuda H; Ozols RF; Lai GM; Fojo A; Rothenberg M; Hamilton TC Cancer Res; 1988 Oct; 48(20):5713-6. PubMed ID: 3139281 [TBL] [Abstract][Full Text] [Related]
30. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681 [TBL] [Abstract][Full Text] [Related]
31. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878 [TBL] [Abstract][Full Text] [Related]
33. Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor. Wen L; Hong D; Yanyin W; Mingyue Z; Baohua L Arch Gynecol Obstet; 2013 May; 287(5):997-1004. PubMed ID: 23212665 [TBL] [Abstract][Full Text] [Related]
34. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794 [TBL] [Abstract][Full Text] [Related]
35. [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol]. Song Y; Shen K; Xu F Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):781-6. PubMed ID: 21176562 [TBL] [Abstract][Full Text] [Related]
36. [Cytokinetic effects of cisplatin on cisplatin-resistant ovarian cancer cell lines]. Sasa H; Kikuchi Y; Hisano A; Ishii K; Nagata I; Kawai T; Aida S; Sugita M; Sugishita T; Tenjin Y Hum Cell; 1992 Dec; 5(4):384-91. PubMed ID: 1304801 [TBL] [Abstract][Full Text] [Related]
37. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579 [TBL] [Abstract][Full Text] [Related]
38. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
39. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Levasseur LM; Greco WR; Rustum YM; Slocum HK Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464 [TBL] [Abstract][Full Text] [Related]
40. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]